First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer

被引：0
|
作者：
Hossein Taghizadeh
Matthias Unseld
Andreas Schmiderer
Angela Djanani
Klaus Wilthoner
Dieter Buchinger
Gerald W. Prager
机构：
[1] Medical University of Vienna,Clinical Division of Oncology, Department of Medicine I
[2] Comprehensive Cancer Center,Clinical Division of Gastroenterology, Hepatology and Metabolism, Department of Internal Medicine I
[3] Medical University Innsbruck,Clinical Division of Oncology, Department of Medicine I
[4] Salzkammergut Klinikum,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Biliary tract cancer; Chemotherapy; Nanoliposomal irinotecan; Progression-free survival; Overall survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：109 / 115
页数：6
相关论文
共 50 条
  • [21] 5-FLUOROURACIL AND FOLINIC ACID IN THE TREATMENT OF METASTATIC COLORECTAL-CANCER - REPLY
    BUDD, GT
    BUKOWSKI, RM
    MCCRACKEN, JD
    MACDONALD, JS
    JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) : 1492 - 1493
  • [22] Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
    Bockorny, Bruno
    Macarulla, Teresa
    Semenisty, Valerya
    Borazanci, Erkut
    Feliu, Jaime
    Ponz-Sarvise, Mariano
    Abad, David Gutierrez
    Oberstein, Paul
    Alistar, Angela
    Munoz, Andres
    Geva, Ravit
    Guillen-Ponce, Carmen
    Fernandez, Mercedes Salgado
    Peled, Amnon
    Chaney, Marya
    Gliko-Kabir, Irit
    Shemesh-Darvish, Liron
    Ickowicz, Debby
    Sorani, Ella
    Kadosh, Shaul
    Vainstein-Haras, Abi
    Hidalgo, Manuel
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 5020 - 5027
  • [23] Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Peeters, M.
    Raoul, J.-L.
    Van Laethem, J.-L.
    Rougier, P.
    Brezault, C.
    Husseini, F.
    Cals, L.
    Zubel, A.
    Vedovato, J.-C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 188 - 188
  • [24] Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil - A prospective cohort study
    Moehler, M
    Gutzler, F
    Steinmann, S
    Boehme, M
    Raeth, U
    Stremmel, W
    Galle, PR
    Rudi, J
    CHEMOTHERAPY, 2003, 49 (1-2) : 85 - 89
  • [25] A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
    Chun, Jung Won
    Woo, Sang Myung
    Lee, Sang Hyub
    Choi, Jin Ho
    Park, Namyoung
    Kim, Joo Seong
    Cho, In Rae
    Paik, Woo Hyun
    Lee, Woo Jin
    Ryu, Ji Kon
    Kim, Yong-Tae
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [26] In vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer
    Inoue, Y
    Tanaka, K
    Hiro, J
    Yoshiyama, S
    Toiyama, Y
    Eguchi, T
    Miki, C
    Kusunoki, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2006, 28 (02) : 479 - 486
  • [27] Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens
    Moehler, M
    Hoffmann, T
    Hildner, K
    Siebler, J
    Galle, PR
    Heike, M
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2002, 40 (12): : 957 - 964
  • [28] COMPARISON OF CFF (CISPLATIN, 5-FLUOROURACIL, FOLINIC ACID) AND MODIFIED DCF (DOCETAXEL, CISPLATIN, 5-FLUOROURACIL) REGIMENS IN THE FIRST LINE TREATMENT OF METASTATIC GASTRIC CANCER
    Kos, F. T.
    Uncu, D.
    Ozdemir, N.
    Budakoglu, B.
    Odabas, H.
    Babacan, N.
    Cihan, S.
    Seker, M.
    Oksuzoglu, B.
    Zengin, N.
    ANNALS OF ONCOLOGY, 2010, 21 : 240 - 240
  • [29] FOLINIC ACID DOES IMPROVE 5-FLUOROURACIL ACTIVITY INVIVO - RESULTS OF A PHASE-III STUDY COMPARING 5-FLUOROURACIL TO 5-FLUOROURACIL AND FOLINIC ACID IN ADVANCED COLON CANCER-PATIENTS
    BOBBIOPALLAVICINI, E
    PORTA, C
    MORONI, M
    SPAGHI, A
    CASAGRANDA, I
    NASTASI, G
    JOURNAL OF CHEMOTHERAPY, 1993, 5 (01) : 52 - 55
  • [30] Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer
    Glimelius, B
    Ristamäki, R
    Kjaer, M
    Pfeiffer, P
    Skovsgaard, T
    Tveit, KM
    Linné, T
    Frödin, JE
    Boussard, B
    Oulid-Aïssa, D
    Pyrhönen, S
    ANNALS OF ONCOLOGY, 2002, 13 (12) : 1868 - 1873
12345